According to the data, 109 antibiotics are currently in the development pipeline, approximately 70 percent of which are in early development (preclinical and phase 1). In contrast, there are 31 at phase 2 and just 9 candidates at phase 3. Despite concerns over antibiotic-resistant pathogens, the data suggests the emergence of new types of antibiotics and strategies that will be available to target pathogens in the future.
Related Articles on Antibiotics:
4 Prognostic Variables Determined to be Risk Factors for MRSA
Varying Antibiotics Equally Effective in Treating Clostridium Difficile Infections
Providers Often Overtreat Enterococcal Bacteria With Antibiotics
